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ABSTRACT 
Oral route of drug administration is the most preferable route because of its flexibility in formulation, ease of administration, and 
patient compliance. But this route has certain limitations like limited gastric residence time (GRT) for sustained drug delivery system 
and for the drugs which are absorb from specific region of gastrointestinal tract (GIT). To overcome these limitations, various 
approaches have been proposed to increase the gastric retention time of the delivery system in the upper part of gastrointestinal tract. 
Gastroretentive dosage form (GRDF) prolongs the GRT by targeting site-specific drug release in upper part of GIT. GRDFs enable 
continuous and the extended duration of drug release and improve bioavailability of drugs that have narrow therapeutic window, by 
this way they prolong dosing interval and increase compliance of the patient. The purpose of this article is to compile the various 
gastroretentive approaches. In order to understand various physiological difficulties to achieve gastric retention, we have 
summarized important factors controlling gastric retention. Finally the evaluation parameters of gastroretentive drug delivery 
systems are covered. The present review addresses briefly about the current status of various leading gastroretentive drug delivery 
technologies, developed until now, i.e. high density (sinking), floating, bio- or mucoadhesive, expandable, unfoldable, super porous 
hydrogel, magnetic systems etc. In addition, important factors controlling gastroretention, advantages and finally, future potential are 
discussed. 
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INTRODUCTION 
Oral sustained drug delivery system is complicated by 
limited gastric residence time. Rapid gastrointestinal 
transit can prevent complete drug release in the 
absorption zone and reduce the efficacy of administered 
dose, since the majority of drugs are absorbed in 
stomach or the upper part of small intestine Floating 
drug delivery offers several applications for drugs 
having poor bioavailability because of the narrow 
absorption window in the upper part of the 
gastrointestinal tract. It retains the dosage form at the 
site of absorption and thus enhances the bioavailability.
1
 
Need for GRDDS 
2
 
• Conventional oral delivery is widely used in 
pharmaceutical field to treat diseases. However,      
conventional delivery had many drawbacks and major 
draw-back is non-site specificity.  
• Some drugs are absorbed at specific site only. They 
require release at specific site or a release such that 
maximum amount of drug reaches to the specific site.  
• Pharmaceutical field is now focusing towards such 
drugs which require site specificity. 
• Gastro-retentive delivery is one of the site specific 
delivery for the delivery of drugs either at stomach or at 
intestine. It is obtained by retaining dosage form into 
stomach and drug is being released at controlled manner 
to specific site either in stomach, duodenum and 
intestine 
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Potential candidates for gastroretentive drug 
delivery system 
1. Drugs that are primarily absorbed in thestomach e.g. 
Amoxicillin. 
2. Drugs that are poorly soluble in alkaline pH e.g. 
Furosemide , Diazepam. 
3. Drugs that have narrow absorption window e.g. 
Levodopa, Methotrexate. 
4. Drugs that degrade in the colon e.g. Ranitidine 
,Metformin HCL. 
5. Drugs that disturb normal colonic microbes e.g. 
Antibiotics against Helicobacter pylori. 
6. Drugs rapidly absorbed from the GI tract e.g.  
Tetracycline. 
7. Drugs acting locally in the stomach. 
3
 
Drug delivery systems are used for maximizing 
therapeutic index of the drug and also for reduction in 
the side effects. The most preferred route is the oral 
route especially for the administration of therapeutic 
drugs because low cost of therapy and ease of 
administration leads to higher level of patient 
compliance. More than 50% of the drug delivery 
systems available are to be administered through oral 
route. Reasons behind using oral route are that it is the 
most promising route of the drug delivery and effective 
oral drug delivery may depend upon many factors such 
as gastric emptying process, gastrointestinal transit time 
of the dosage form, drug release from the dosage form 
and site of absorption of drug. High level of patient 
compliance is the major advantage of using the oral 
route. To modify the GI transit time is one of the main 
challenge in the development of oral controlled drug 
delivery system. Gastric emptying of pharmaceuticals is 
highly variable and dependent on the dosage form and 
the fed/fasted state of the stomach. Normal gastric 
residence time usually ranges between 5 minutes to 2 
hours. In the fasted state the electrical activity in the 
stomach – the interdigestive myoelectric cycle or 
migrating myoelectric complex (MMC) governs the 
activity and the transit of dosage forms. It is 
characterized by four Phases.
 4
 
 Anatomy of the stomach 
The gastro intestinal tract can be divided into three main 
regions 
a) Stomach 
b) Small intestine- duodenum, jejunum, and ileum 
c) Large intestine 
The GIT is a muscular tube of about 9m which extends 
from mouth to anus. Its function is to take nutrients and 
eliminate out waste product by physiological processes 
such as digestion, absorption, secretion, motility and 
excretion. The stomach has three muscle layercalled 
oblique muscles and it is situated in the proximal part of 
the stomach, branching over the fundus and higher 
regions of the gastric body. The stomach is divided into 
fundus, body and pylorus 
[8]
. The stomach is a shaped 
organ located in the upper left hand portion of the 
abdomen. The main function of the stomach is to store 
the food temporarily, grind it and releases slowly in to 
the duodenum. 
 
Figure 1: General Gastrointestinal tract
33 
Physiology of the stomach 
The stomach is an expanded section of the digestive 
tube between the esophagus and small intestine. In the 
empty state the stomach is contracted and its mucosa 
and sub mucosa are thrown up into folds calledrugae. 
There are 4 major types of secretory a epithelial cell that 
covers the stomach and extends into gastric pits and 
glands. 
1. Mucous cells- secrete alkaline mucus 
2. Parietal cells – secrete HCL 
3. Chief cells- secrete pepsin 
4. G cells- secrete hormone gastrin. 
5
 
Gastric motility and gastric empty rate 
Two distinct patterns of gastrointestinal motility and 
secretion exist to the fasted and fed state.  
 
Figure 2: Phases of Gastic motility and gastric 
emptying rate
34
 
The bioavailability of the orally administered drug 
depend upon the state of feeding. In the fasted state, it is 
characterized by an interdigestive series of electric event 
called inter digestive myoelectric cycle or 
migratingmotorcomplex. It is divided into 4 phases 
[5].
 
More et al                                                                                                               Journal of Drug Delivery & Therapeutics. 2018; 8(4):24-35 
ISSN: 2250-1177                                                                             [26]                                                                             CODEN (USA): JDDTAO 
a) Phase I (basal phase) it lasts from 40-60 minwith rare 
contractions 
b) Phase II (preburust phase) last from 40-60minwith 
intermittent potential and contractions. 
c) Phase III (burst phase) last for 4-6 min. in this intense 
and regular contraction occur for short periods. Due to 
these contractions theundigestive food is swept from 
stomach to intestine. These are known as house keeper 
waves. 
d) Phase IV it lasts for 0-5 min and occurs between 
phases III and I for two consecutive cycles. 
After the ingestion of the mixed meal the pattern of 
contraction changes from fed to that of fasted state, this 
is known as digestive motility pattern, these contractions 
reduces the size of the food particles toless than 1mm 
after that it is propelled to the pylorus in the suspension 
form. During fed state the onset of MMC is delayed 
which result in slow down of gastric emptying rate.
6
 
 
Figure 3: Shows Physiology of stomach
35 
Advantages of gastroretentive drug delivery system 
6, 
7.
 
1. It increases patient compliance by reducing dosing 
frequency 
2. Buoyancy increases gastric residence time 
3. Better therapeutic effect of short half-life drugs 
4. Site specific drug delivery to stomach can be 
achieved 
5. Gastric irritation can be avoided by designing 
sustained release. 
6. No risk of dose dumping by making single unit 
floating unit such as microspheres releases drug 
uniformly. 
[7]
 
8. Delivery of drugs with narrow absorption window in 
the small intestine region. 
9. Longer residence time in the stomach could be 
advantageous for local action in the upper part of the 
small intestine, for example treatment of peptic ulcer 
disease. 
10. Improved bio-availability is expected for drugs that 
are absorbed readily upon release in the GI tract such as 
cyclosporine, ciprofloxacin, ranitidine, amoxicillin, 
captopril,etc. 
11. Targeted therapy for local ailments in the upper GI 
tract.
8
 
 
Disadvantages of gastroretentive drug delivery 
system 
9
 
1) Floating systems has limitation, that they require high 
levelof fluids in stomach for floating and working 
efficiently. So more water intake is prescribed with such 
dosage form. 
2) In supine posture (like sleeping), floating dosage form 
may swept away (if not of larger size) by contractile 
waves. So patient should not take floating dosage form 
just before going to bed. 
3) Drugs having stability problem in high acidic 
environment, having very low solubility in acidic 
environment and drugs causing irritation to gastric 
mucosa cannot be incorporated into GRDDS. 
4) Bio/mucoadhesives systems have problem of high 
turnover rate of mucus layer, thick mucus layer & 
soluble mucus related limitations. 
5) Swellable dosage form must be capable to swell fast 
before its exit from stomach and achieve size larger than 
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pylorus aperture. It must be capable to resist the 
housekeeper waves of Phase III of MMC. 
6) Gastric retention is influenced by many factors such 
as gastric motility, pH and presence of food. These 
factors are never constant and hence the buoyancy 
cannot be predicted. 
7) The major challenge for a bio adhesive system is the 
high turnover rate of gastric mucus. 
8) There is also possibility of esophageal binding with 
bio adhesive drug delivery systems. 
9) Drugs which have stability and solubility problems in 
GIT are not suitable candidates for these types of 
systems. 
Gastroretentive Techniques 
Several techniques, including floating, 
swelling,inflation, and adhesion have been explored 
toincrease the gastro retention of dosage forms
3
 
 
 
 
 
   
 
  
 
 
 
Figure 4: Gastroretentive Techniques 
 
TYPES OF GASTRORETENTIVE DOSAGE 
FORM 
A) Floating systems 
10
 
Floating systems are low-density systems that have 
sufficient buoyancy to float over the gastric contents 
and remain in the stomach for a prolonged period. 
While the system floats over the gastric contents, the 
drug is released slowly at the desired rate which results 
in increased GRT and reduces fluctuation in plasma 
drug concentration. The floating drug delivery system 
and bio adhesive drug delivery are widely used 
technique for gastro retention and floating systems in 
particular has been extensively researched, mainly 
because the floating system does not adversely affect 
the motility of GI tract. Floating systems can also be 
classified as effervescent and noneffervescent systems. 
 
 
Figure 5: Mechanism of floating systems
36 
I) Effervescent systems 
Floatation of a drug delivery system in the stomach 
filled with vacuum, air, or an inert gas. Gas can be 
introduced into the floating chamber by the volatilization 
of an organic solvent (e.g., ether or cyclopentane) or by 
the CO2 produced as a result of an effervescent reaction 
between organic acids and carbonate–bicarbonate salts. 
These devices contain a hollow deformable unit that 
converts from a collapsed to an expanded position and 
returns to the collapsed position after a pre determined 
amount of time to permit the spontaneous ejection of 
thin floatable system from the stomach. 
EXPANDABLE, 
UNFOLDABLE SYSTEMS 
 
BIO/MUCO–ADHESIVE 
SYSTEMS 
 
SWELLING SYSTEMS 
 
SUPER POROUS 
HYDROGEL SYSTEMS  
 
FLOATING DRUG 
DELIVERY SYSTEMS 
 
RAFT FORMING 
SYSTEM 
 
MAGNETIC SYSTEMS 
 
HIGH DENSITY 
SYSTEMS 
 
TYPES OF 
DOSAGE FORM 
FOR GRDDS 
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a) Volatile liquid containing systems 
This type of system consists of two chambers separated 
by an impermeable, pressure-responsive, movable 
bladder. The first chamber contains the drug and the 
second chamber contains the volatile liquid. The GRT of 
a drug delivery system can be sustained by incorporating 
an inflatable chamber, which contains a liquid e.g. ether, 
cyclopentane, that gasifies at body temperature to cause 
the inflatation of the chamber in the stomach. The device 
may also consist of a bio erodible plug made up of Poly 
vinyl alcohol, Polyethylene, etc. that gradually dissolves 
causing the inflatable chamber to release gas and 
collapse after a predetermined time to permit the 
spontaneous ejection of the inflatable systems from the 
stomach. The device inflates, and the drug is 
continuously released from the reservoir into the gastric 
fluid.
 11.
 
b) Gas generating system 
Floatability can also be achieved by generation of gas 
bubbles. CO2 can be generated in situ by the 
incorporation of carbonates or bicarbonates, which react 
with acid- either the natural gastric acid or coformulated 
as citric or tartaric acid. The optimum stoichiometric 
ratio of citric acid and sodium bicarbonate for gas 
generation is reported to be 0.76:1. An alternative is to 
incorporate a matrix with entrapped of liquids, which 
forms a gas at body temperature. These approaches have 
been used for single and multiple unit system. 
 
Figure 6: Gas generating system
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II.) Non effervescent systems 
12
 
Noneffervescent systems incorporate a high level (20–75 
% w/w) of one or more gel-forming, highly swellable, 
cellulosic hydrocolloids (e.g., hydroxyethyl cellulose, 
hydroxypropyl cellulose,hydroxypropyl methylcellulose 
(HPMC), and sodium carboxymethyl cellulose), 
polysaccharides, or matrixforming polymers (e.g., 
polycarbophil, polyacrylates, and polystyrene) into 
tablets or   capsules. Upon coming into contact with 
gastric fluid, these gel formers, polysaccharides and 
polymers hydrate and form a colloidal gel barrier that 
controls the rate of fluid penetration into the device and 
consequent drug release. As the exterior surface of the 
dosage form dissolves, the gel layer is maintained by the 
hydration of the adjacent hydrocolloid layer. The air 
trapped by the swollen polymer lowers the density and 
confers buoyancy to the dosage form. The following 
approaches used in designing intragastric floating 
systems
. 
a) Hydrodynamically balanced systems OR 
Colloidal Gel Barrier System:  
These are single unit dosage form, containing one or 
more gel forming hydrophilic polymers, HPMC is the 
most commonly used excipient, although HEC, HPC, 
NaCMC, agar and alginic acid are also used. The 
polymer is mixed with drug and usually administered in 
a gelatin capsule. The capsules rapidly dissolve in the 
gastric fluid, and hydration and swelling of the surface 
polymer produce a floating mass. Drug release is 
controlled by the formation of hydrated boundary at the 
surface. Continuous erosion of the surface allows water 
penetration to the inner layer, maintaining surface 
hydration and buoyancy. Incorporation of fatty 
excipients gives low density formulations and reduces 
penetration of water, reducing the erosion. The main 
drawback is the passivity of operation. It depends on the 
air sealed in the dry mass Centre following hydration of 
gelatinous surface layer and hence the characteristics 
and amount of polymer. Effective drug delivery depends 
on the balance of drug loading and effect of polymer on 
its release profile. 
b.) Microporous compartment system  
This technology is based on the encapsulation of a drug 
reservoir inside a microporous compartment with pores 
along its top and bottom walls. The peripheral walls of 
the drug reservoir compartment are completely sealed to 
prevent any direct contact of gastric surface with the un-
dissolved drug. In the stomach, the floatation chamber 
contains trapped air causes the delivery system to float 
over the gastric content. Gastric fluid enters through the 
aperture dissolves the drug and carries the dissolved 
drug for continuous transport across the intestine for 
absorption 
c. Alginate beads  
Multi-unit floatingdosage forms have been developed 
from freezedriedcalcium alginate. Spherical beads 
ofapproximately 2.5 mm in diameter can be preparedby 
dropping sodium alginate solution into aqueoussolution 
of calcium chloride, causing theprecipitation of calcium 
alginate. The beads arethen separated, snap-frozen in 
liquid nitrogen, andfreeze-dried at -40ºC for 24 hours, 
leading to theformation of a porous system, which can 
maintain a floating force for over 12 hours. These 
floating beads gave a prolonged residence time of 
morethan 5.5 hours.
 13
 
d. Micro balloons or Hollow Microspheres 
14.
 
Micro balloons / hollow microspheres loaded with drugs 
in their other polymer shelf were prepared by simple 
solvent evaporation or solvent diffusion method to 
prolong the GRT of the dosage form. Commonly used 
polymers to develop these systems are polycarbonate, 
cellulose acetate, calcium alginate, Eudragit S, agar and 
low methoxylated pectin etc. Buoyancy and drug release 
from dosage form are dependent on quantity of 
polymers, the plasticizer polymer ratio and the solvent 
used for formulation. These micro balloons floated 
continuously over the surface of an acidic dissolution 
media containing surfactant for >12 hours. At present 
hollow microspheres are considered to be one of the 
most promising buoyant systems because they combine 
the advantages of multiple-unit system and good 
floating. 
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B) Bio/mucoadhesive systems 
Bio adhesive drug delivery systems (BDDS) are used as 
a delivery device within the lumen to enhance drug 
absorption in a site specific manner. This approach 
involves the use of bio adhesive polymers, which can 
adhere to the epithelial cell surface or mucin in the 
stomach. It increases the GRT by increasing the 
intimacy and duration of contact between the dosage 
form and the biological membrane. The adherence to the 
gastric wall increases residence time at a particular site, 
thereby improving bioavailability. Gastric mucoadhesion 
does not tend to be strong enough to impart to dosage 
forms the ability to resist the strong propulsion forces of 
the stomach wall. The continuous production of mucous 
by the gastric mucosa to replace the mucous that is lost 
through peristaltic contractions and the dilution of the 
stomach content also seem to limit the 
potentialofmucoadhesion as a gastro retentive force. 
Some of the most promising excipients that have been 
used are polycarbophil, carbopol, lections, chitosan 
andgliadin, etc. BDDS are used as a delivery device 
within the human to enhance drug absorption in a site-
specific manner.
 15 
 
 
Figure 7: Bio-adhesion System
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The basis of adhesion in that a dosage form can stick to 
the mucosal surface by different mechanism. These 
mechanisms are:  
1) The wetting theory, which is based on the ability of 
bio adhesive polymers to spread and develop intimate 
contact with the mucous layers.  
2) The diffusion theory which proposes physical 
entanglement of mucin strands the flexible polymer 
chains, or an interpenetration of mucinstrands into the 
porous structure of the polymer substrate.  
3) The absorption theory, suggests that bio adhesion due 
to secondary forces such as Vander Waal forces and 
hydrogen bonding.  
4) The electron theory, which proposes attractive 
electrostatic forces between the glycoprotein mucin 
network and the bio adhesive material.  
Binding of polymers to the mucin/epithelial surface can 
be divided into three categories:  
a. Hydration – mediated adhesion- 
Certain hydrophilic polymers have the tendency to 
imbibe large amount of water and become sticky, 
thereby acquiring bio adhesive properties. The 
prolonged gastro retention of the bio/muco-adhesive 
delivery system is further controlled by the dissolution 
rate of the polymer.  
b. Bonding –mediated adhesion 
The adhesion of polymers to a mucus or epithelial cell 
surface involves various bonding mechanisms including 
physical, mechanical and chemical bonding. Physical or 
mechanical bonds can result from deposition and 
inclusion of the adhesive material in the crevices of the 
mucosa. Chemical bonds may be either covalent 
(primary) or ionic (secondary) in nature. Secondary 
chemical bonds consist of dispersive interactions (i.e. 
Vander Waals interactions) and stronger specific 
interactions such as hydrogen bonds. The hydrophilic 
functional groups responsible for forming hydrogen 
bonds are the hydroxyl and carboxylic groups.
16
 
c. Receptor – mediated adhesion-  
Certain polymers have the ability to bind to specific 
receptor sites on the cell surface. The receptor mediated 
events serves as a potential approach in bio/muco- 
adhesion, hence enhancing the gastric retention of 
dosage forms. Certain plant lections, like tomato 
lections, interact specifically with the sugar groups 
present in mucus or on the glycocalyx. 
17 
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C) Expandable, unfoldable and swellable systems 
18, 
19 
A dosage form in the stomach will withstand gastric 
transit if it bigger than pyloric sphincter. However,the 
dosage form must be small enough to beswallowed, and 
must not cause gastricobstruction either singly or by 
accumulation. Thus, their configurations are required to 
develop anexpandable system to prolong GRT:  
1) A small configuration for oral intake,  
2) An expanded gastro retentive form, and  
3) A final small form enabling evacuation following 
drug release from the device.  
 
Figure 8: Unfold able and swellable systems
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Thus, gastro-retention is improved by the combination 
of substantial dimension with high rigidity of dosage 
form to withstand peristalsis and mechanical 
contractility of the stomach. Unfold able and Swellable 
systems have been investigated and recently tried to 
develop an effective GRDDS. Unfold able systems are 
made of biodegradable polymers. They are available 
indifferent geometric forms like tetrahedron, ring or 
planner membrane (4 - label disc or 4 - limbed cross 
form) of bio erodible polymer compressed within 
capsule which extends in the stomach. Swellable 
systems are also retained in the GIT due to their 
mechanical properties. The swelling is usually results 
from osmotic absorption of water. Expandable systems 
have some drawbacks like problematical storage of 
much easily hydrolysable, biodegradable polymers 
relatively short-lived mechanical shape memory for the 
unfolding system most difficult to industrialize and not 
cost effective. Again, permanent retention of rigid, large 
single-unit expandable drug delivery dosage forms may 
cause brief obstruction, intestinal adhesion and 
gastropathy. 
D) High-density systems 
These systems, which have a density of ~3 g/cm3, are 
retained in the rugae of the stomach and are capable of 
withstanding its peristaltic movements. Above a 
threshold density of 2.4–2.8 g/cm3, such systems can be 
retained in the lower part of the stomach. The only 
major drawbacks with such systems is that it is 
technically difficult to manufacture them with a large 
amount of drug (>50 %) and to achieve the required 
density of 2.4–2.8 g/cm3. Diluents such as barium 
sulphate (density = 4.9), zinc oxide, titanium dioxide, 
and iron powder may be used to manufacture such high-
density formulations. 
E. Magnetic Systems  
This approach to enhance the GRT is based on the 
simple principle that the dosage form contains a small 
internal magnet, and a magnet placed on the abdomen 
over the position of thestomach. Although magnetic 
system seems to work, the external magnet must be 
positioned with a degree of precision that might 
compromise patient compliance. The technological 
approach in rabbits with bio adhesive granules 
containing ultra-fine ferrite. They guided them to 
esophagus with an external magnet for the initial 2 
minutes and almost all the granules were retained in the 
region after 2hours 
20 
F) Raft-forming System 
Raft System incorporate alginate gels these have a 
carbonate component and, upon reaction with gastric 
acid, bubbles form in the gel, enabling floating. Raft 
forming systems have received much attention for the 
drug delivery for GI infections and disorders. The 
mechanism includes the formation of viscous cohesive 
gel in contact with gastric fluids, wherein each portion 
of the liquid swells forming a continuous layer called a 
raft. This raft floats on gastric fluids because of low bulk 
density created by the formation of CO2. Usually, the 
system ingredients includes age forming agent and 
alkaline bicarbonates or carbonates responsible for the 
formation of CO2 to make the system less dense and 
float on the gastric fluids An antacid raft forming 
floating system contains a gel forming agent (e.g. 
sodium alginate), sodium bicarbonate and acid 
neutralizer, which forms a foaming sodium alginate gel 
(raft), which when comes in contact with gastric fluids, 
the raft floats on the gastric fluids and prevents the 
reflux of the gastric contents (i.e. gastric acid) into the 
esophagus by acting as barrier between the stomach and 
esophagus.
21
 
G) Super porous Hydrogels 
22.
 
Although these are swellable systems, they differ 
sufficiently from the conventional type to warrant 
separate classification. With pore size ranging between 
10nm and 10 m, absorption of water by conventional 
hydrogels is very slow process and several hours may be 
needed to reach an equilibrium state during which pre 
mature evacuation of dosage form may 
occur.Superporous hydrogels, average pore size > 
100 m, swell to equilibrium size within a minute, due 
to rapid water up take by capillary wetting through 
numerous interconnected open pores. 
H) Swelling systems
23.
 
After being swallowed, these dosage forms swell to a 
size that prevents their passage through the pylorus. As 
a result, the dosage form is retained in the stomach for a 
long period of time. These systems are sometimes 
referred to as plug type systems because they tend to 
remain lodged at the pyloric sphincter. These polymeric 
matrices remain in the gastric cavity for several hours 
even in the fed state. Sustained and controlled drug 
release may be achieved by selecting a polymer with the 
proper molecular weight and swelling properties. Upon 
coming in contact with gastric fluid, the polymer 
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imbibes water and swells. The extensive swelling of 
these polymers is a result of the presence of physical–
chemical crosslinks in the hydrophilic polymer network. 
These crosslink’sprevent the dissolution of the polymer 
and thus maintain the physical integrity of the dosage 
form. A balance between the extent and duration of 
swelling is maintained by the degree of cross linking 
between the polymeric chains. A high degree of cross 
linking retards the swelling ability of the system and 
maintains its physical integrity for a prolonged period. 
On the other hand, a low degree of cross linking results 
in extensive swelling followed by the rapid dissolution 
of the polymer. An optimum amount of cross linking is 
required to maintain a balance between swelling and 
dissolution. The swollen system eventually will lose its 
integrity because of a loss of mechanical strength caused 
by abrasion or erosion or will burst into small fragments 
when the membrane ruptures because of continuous 
expansion. These systems also may erode in the 
presence of gastric juices so that after a predetermined 
time the device no longer can attain or retain the 
expanded configuration. 
FACTORS AFFECTING GASTRIC RESIDENCE 
TIME OF GRDDS 
24
 
Gastric retention time (GRT) is depends upon the 
dosage form buoyancy which is further dependent on 
the density. Density of the dosage form that is used for 
GRDDS should be less than the gastric contents 
(1.004gm/ml).  
1) Size and Shape  
Dosage form unit with a diameter of more than 7.5 mm 
are more suitable candidate as compared to those which 
have a diameter of 9.9 mm because they have an 
increased GRT. Similarly the dosage form having a 
tetrahedron shape and ring shape devises with a flexural 
modulus of 48 and 22.5 kilopond per square inch (KSI) 
are reported to have better GIT for 90 to 100% retention 
and hence more suitable for GRDDS as compared with 
other shapes.  
2) Viscosity of polymer  
Viscosity of polymer and their interaction greatly affect 
the drug release and rafting properties of GRDDS. Low 
viscosity polymers (e.g., HPMC K100LV) were found 
to be more suitable candidates for GRDDS than high 
viscosity polymers (e.g., HPMC K4M) because they 
improve rafting properties. Also, with an increase in 
polymer viscosity a decrease in the release rate was 
observed.  
3) Fed or Unfed State  
Under fasting conditions, the GRT of the unit is 
expected to be very short because of the periods of 
strong motor activity or the migrating myoelectric 
complexes (MMC) that occurs every 1.5to 2 hours. The 
MMC sweeps undigested material from the stomach and 
if the timing of administration of the formulation 
coincides with that of the MMC then obviously GRT of 
the dosage form expected to be very short. But, in the 
fed state, GRT is considerably longer because MMC is 
delayed.  
4) Nature of meal  
Motility pattern of the stomach can change to fed state 
when indigestible polymers or fatty acid salts are fed 
and because of this the gastric emptying rate is 
decreased and drug release is prolonged.  
5) Frequency of feed  
When successive meals are given, the GRT can increase 
by over 40 minutes compared with a single meal 
because of the low frequency of MMC.  
6) Gender 
Mean GRT of a male in meals (3.4±0.4 hours) is less 
compared to the female of the same age and race 
(4.6±1.2 ours), regardless of the height, weight, and 
body surface of the two.  
7) Age 
Elderly people have a significantly longer GRT, 
especially those who are over 70 years of age. 
8) Posture 
Rafting forms are protected by an upright position 
against postprandial emptying because at this position, 
the rafting form remains above the gastric contents 
irrespective of its size. While the conventional dosage 
form sink to the lower part of the distal stomach at this 
position from where they are expelled by astral 
peristaltic movements through the pylorus. But supine 
position offers no such protection against early and 
erratic emptying of rafting dosage forms. Only large 
dosage forms (both conventional and rafting) experience 
prolonged retention when they are anywhere between 
the lesser and greater curvature of the stomach. On 
moving distally, these units show significant reduction 
in GRT compared with upright subjects because of 
peristaltic movement. 
9) Gastro retentive dosage form 
Gastro retentive dosage forms are the systems that can 
stay in the gastric region for several hours and thus, 
prolong the gastric residence time of the drugs. After 
oral administration, such a dosage form is retained in the 
stomach and releases the drug in a controlled and 
sustained manner so that the drug can be supplied 
continuously in the upper GIT. This prolonged gastric 
retention improves bioavailability, decreases drug 
wastage, and improves solubility of drugs that are less 
soluble in a high pH environment. 
10) Other factors:- 
a) Diseased states of the individual (chronic disease, 
diabetes etc.) 
b) Body mass index 
c) Physical activity 
d) Molecular weight and lipophilicity of the drug 
depending on its ionization state.
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Criteria for selection of drug 
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For Gastro retentive drug delivery system 
More et al                                                                                                               Journal of Drug Delivery & Therapeutics. 2018; 8(4):24-35 
ISSN: 2250-1177                                                                             [32]                                                                             CODEN (USA): JDDTAO 
1. Drugs those are locally active in the stomach (e.g. 
misoprostol, antacids) 
2. Drugs that have narrow absorption window in GIT 
(e.g. L-DOPA, paminobenzoic acid, furosemide, 
riboflavin). 
3. Drugs those are locally active in the stomach (e.g. 
misoprostol, antacids). 
4. Drugs exhibit low solubility at high pH values (e.g. 
diazepam, chlordiazepoxide,verapamil). 
5. Drugs that disturb normal colonic microbes such as 
tetracycline, clarithromycin, amoxicillin 
6. Drugs those are unstable 
Ideal Characteristics 
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1. Drugs acting locally in the stomach, e.g. Antacids and 
drugs for H. Pylori viz., Misoprostol  
2. Drugs that are primarily absorbed in the stomach and 
upper part of GI, e.g. Amoxicillin, Calcium 
Supplements, Chlordiazepoxide and Cinnarazine 
3. Drugs that is poorly soluble at alkaline pH, e.g. 
Furosemide, Diazepam, Verapamil HCL, 
Chlordiazepoxide etc.  
4. Drugs with a narrow window of absorption in GIT, 
e.g. Riboflavin, ParaAminobenzoic Acid, Cyclosporine, 
Methotrexate, Levodopa etc.  
5. Drugs which are absorbed rapidly from the GI tract. 
e.g. Metronidazole, tetracycline.  
6. Drugs that degrade or unstable in the colon. e.g. 
Captopril, Ranitidine HCL, Metronidazole, Metformin 
HCl.  
7. Drugs that disturb normal colonic microbes, e.g. 
Amoxicillin Trihydrate, antibiotics against Helicobacter 
pylori.
 
Table 1: List of Drugs Formulated in Multiple Unit Forms of Floating Drug Delivery Systems 
Drug Dosage form Drug Dosage form 
Verapamil Hydrochloride Floating Micro particles 
Ketoprofen Floating Micro particles 
Ranitidine Hydrochloride Floating Granules Ranitidine Hydrochloride Floating Granules 
Metronidazole Floating Beads Metronidazole Floating Beads 
Lansoprazole Floating Micro pellets Lansoprazole Floating Micro pellets 
Meloxicam Low density multiparticulate system 
Diltiazem Hydrochloride, Theophylline & Verapamil Hydrochloride Theophylline andMicro particles 
Nifedipine Hollow Microsphere Acetohydroxamic Acid Floating Microsphere 
Nifedipine Hollow Microsphere Acetohydroxamic Acid Floating Microsphere 
Piroxicam Floating Microsphere Residronate Sodium Granules 
Diltiazem Hydrochloride Granules  
Piroxicam Floating Microsphere Residronate Sodium Granules 
 
Approaches for gastro retention: 
To improve the retention of an oral dosage form in the 
stomach various approaches have been developed, it 
includes floating systems and non-floating systems. 
Floating systems includes effervescent systems and non-
effervescent systems, these systems have the bulk 
density lower than the gastric fluid and remain floating 
and releases the drug slowly in a desired rate. Non 
floating systems include bio adhesive systems, swelling 
systems, high density systems expandable systems, raft 
forming systems, magnetic systems which utilize 
different mechanisms to prevent the exit of drugs 
through pyloric sphincters. 
28 
 
 
Figure 9: Approaches for gastro retention
40 
More et al                                                                                                               Journal of Drug Delivery & Therapeutics. 2018; 8(4):24-35 
ISSN: 2250-1177                                                                             [33]                                                                             CODEN (USA): JDDTAO 
 
Figure 10: Flowchart showing different approaches for gastro retentive drug delivery systems 
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EVALUATION PARAMETERS OF 
GASTRORETENTIVE DOSAGE FORMS: 
29, 30
 
A) In- Vitro Evaluation 
1) General tests: These tests include appearance, 
hardness, friability, drug content, weight 
Variation, uniformity of content. 
2) Floating systems 
a) Buoyancy Lag Time:  
Buoyancy lag time is determined to assess the time 
taken bythe dosage form to float on the top of the 
dissolution medium, after it is placed in the medium. 
These parameters can be measured as a part of the 
dissolution test. 
b) Floating Time: 
The time for which the dosage form continuously floats 
on the dissolution media is termed as floating time. It is 
usually performed in Simulated Gastric Fluid 
maintained at 370°C. 
c) Specific Gravity / Density:  
Density can be determined by the displacement method 
using Benzenes displacement medium. 
3) Swelling systems 
a) Swelling Index:  
After immersion of swelling dosage form into Simulated 
Gastric Fluid at 370
C
, dosage form is removed out at 
regular interval and dimensional changes are measured 
in terms of increase in tablet thickness / diameter with 
time. 
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B) In-Vivo Evaluation 
1) Radiology: 
Barium Sulphate is widely used as Radio Opaque 
Marker. X-ray is used for examination of internal body 
systems. So, BaSO4 is incorporated inside dosage form 
and X-ray images are taken at various intervals to view 
gastric retention. 
2) Gastroscopy: Gastroscopy is used to inspect visually 
the effect of prolongation in stomach. 
3) Scintigraphy: Similar to X-ray, emitting materials 
are incorporated into dosage form and then images are 
taken by scintigraphy. Widely used emitting material is 
99 Tc. 
4) Ultrasonography: It is not used generally because it 
is not traceable at intestine. 
5) Magnetic Marker Monitoring: This technique is 
radiation less and so not hazardous. In this technique, 
dosage form is magnetically marked by incorporating 
iron powder inside, and images can be taken by very 
sensitive bio-magnetic measurement equipment. 
In vivo evaluation of gastric retention 
31, 32 
Analysis of the position of the dosage form in the GIT 
involves an imaging technique such as γ-scintigraphy 
and X-ray. 1) In γ-scintigraphy, a small amount of stable 
isotope is compounded in the dosage forms during its 
preparation. The inclusion of a γ-emitting radio-nuclide 
in a formulation allows indirect external observation 
using a γ-camera or scinti scanner. For x-ray, barium 
sulfate is used as a contrast medium. It helps to locate 
dosage form in the GIT by which one can predict and 
correlate the gastric emptying time and the passage of 
dosage form. In addition, gastroscopy and 
ultrasonography studies can be included in the in vivo 
evaluation of GRDDS. Gastroscopy comprises of per-
oral endoscopy, used with a fiber optic and video 
systems. Ultrasonography is not routinely used in the 
evaluation of GRDDS. In vivo plasma profile can also 
be obtained by performing the study in suitable animal 
model.  
 Water uptake study: It is done by immersing the 
dosage form in simulated gastric fluid at 37OC and 
determining the dimensional changes, such as diameter 
and thickness, at regular interval of time. After the 
stipulated time the swollen tablets are weighed and 
water uptake is measured in the terms of percentage 
weight gain, as given:  
WU= (Wt-Wo) X 100/Wo 
In which, Wt and Wo are the weight of the tablet after 
time t and initially, respectively. The tablets are also 
evaluated for hardness, friability, weight variation etc. 
which are applicable for conventional instant release 
tablets. For the multiple unit dosage forms like 
microsphere following tests are also essential apart from 
the above tests:  
1) Morphological and dimensional analysis: It is done 
with the aid of scanning electron microscopy and optical 
microscope.  
2) Percentage yield of microsphere.  
3) Entrapment efficiency: The drug is extracted by 
suitable method and analyzed to find out the amount of 
drug present.  
 
Patents on Grdds 
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Sr.No Patents  
1 Gastrorentevive dosage form systems and process of preparation thereof. US20140271871846 
2 Gastrorentevive sustained and pulsatile drug delivery systems W02013051036 A1 
3 GRDDS and their dosage form their method of preparation using calcium carbonate. W02014057086 A1 
4 A novel gastro retentive drug delivery of macrolide. W02011125075 A3 
5 Gastrorentevive controlled release microsphere for improved drug delivery US6207197 B1 
6 Extended release gastro retentive oral drug delivery systems for valsartan EP2061438 A1 
7 GRDDS. W02009089665 A2 
8 GRDDS comprising an extruded hydratable polymer. US8586083 B2 
 
CONCLUSION 
Gastro retentive drug delivery system offers a potential 
advantage of enhanced bioavailability and controlled 
delivery of drug. Gastro retentive drug delivery system 
showed the potential to increase the gastric retention of 
drug. Growing understanding of impact of GIT 
physiology on drug delivery will ensure development of 
an increasing number of drug delivery system to 
optimize drug delivery of molecules exhibiting regional 
variability in drug absorption. The increasing 
sophistication of delivery technology will ensure the 
development of increase number of gastro retentive drug 
delivery to optimize the delivery of molecules that 
exhibit absorption window, low bioavailability and 
extensive first pass metabolism. Based on the literature 
surveyed, we concluded that Gastro retentive drug 
delivery offers various potential advantages for drug 
with poor bioavailability due their absorption is 
restricted to the upper gastrointestinal tract and they can 
be delivered efficiently thereby maximizing their 
absorption and enhancing absolute bioavailability . 
Gastro retentive drug delivery system gives maximum 
benefit to patient. 
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